Analysis of adverse reactions in immunotherapy for 127 cases of non-small cell lung cancer
Objective:To analyze the occurrence characteristics and clinical manifestations of adverse reactions(ADR)of immunotherapy in 127 cases of non-small cell lung cancer(NSCLC),and to provide evidence for timely detection and control on the risks of drug safety.Methods:127 patients with NSCLC treated with immunotherapy from July 2019 to May 2023 were analyzed by gender and age,ADR-involved organs/systems and clinical manifestations,and ADR subgroups.Results:Among 127 patients,114 patients had ADR,of which 91 were male,accounting for 79.82%.ADR patients aged 60 to 74 years were the most common,accounting for 50 cases(43.86%).The most common ADR was digestive system and blood/lymphatic system damages,and nausea in 55 cases,vomiting in 53 cases,myelosuppression in 48 cases.Conclusion:There is a high probability of ADR events in NSCLC patients over 60 years old receiving immunotherapy,especially in the digestive system and the blood/lymphatic system.Since ADR of the blood/lymphatic system has a great impact on the therapeutic effect of the disease,the adverse reactions of the blood/lymphatic system should be monitored clinically.